Healthcare diagnostics company Labcorp Holdings (NYSE: LH) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.8% year on year to $3.73 billion. The company’s outlook for the full year was close to analysts’ estimates with revenue guided to $14.77 billion at the midpoint. Its non-GAAP profit of $4.99 per share was 4.6% above analysts’ consensus estimates.

Is now the time to buy LH? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Labcorp’s second quarter results were well received by the market, as the company delivered solid revenue growth and exceeded Wall Street’s non-GAAP profit expectations. Management attributed the quarter’s performance to continued momentum in specialty testing, strong execution in its Diagnostics and Biopharma Laboratory Services segments, and expanding partnerships with health systems. CEO Adam Schechter highlighted that double-digit growth in specialty areas such as oncology and neurology, along with the nationwide launch of new tests like ColoSense, contributed meaningfully to the quarter. The company also noted progress in consumer-initiated testing, supported by digital innovations and expanded payer coverage.

Looking forward, Labcorp’s updated guidance for the year reflects optimism in both Diagnostics and Biopharma Laboratory Services, backed by ongoing investments in specialty testing, technology, and consumer health offerings. Management expects Central Labs to maintain strong top-line growth, with Early Development also showing improved outlook due to strategic actions and timely study starts. CFO Julia Wang stated that margin expansion across both segments is anticipated, supported by operating efficiencies and the benefits of the company’s Launchpad initiative. The company believes that continued execution in high-growth areas and disciplined capital allocation will support sustainable profit growth for the remainder of the year.

Key Insights from Management’s Remarks

Labcorp’s management emphasized that Q2’s performance was propelled by specialty testing growth, successful product launches, and operational efficiency across its two core businesses.

• Specialty testing momentum: Labcorp saw double-digit revenue growth in specialty testing areas like oncology, neurology, autoimmune disease, and women’s health, helping to win new health system and provider customers. Management indicated that oncology patients, in particular, drive higher testing volumes and are a key growth area.
• Consumer business expansion: The consumer-initiated testing segment delivered strong double-digit growth, driven by demand for at-home and digital health solutions. The nationwide launch of the ColoSense test—an FDA-approved, RNA-based colorectal cancer screening product—was highlighted as a potential new driver, particularly as payer and Medicare coverage expands.
• Strategic partnerships and acquisitions: Labcorp expanded its network through the acquisition of outreach laboratory services from Parkview Health and Tribal Diagnostics, and secured a Department of Defense contract to provide testing for military families globally. These moves are intended to broaden access and strengthen long-term growth.
• Technology and digital initiatives: The launch of the AI-powered MyLabcorp app and integration with Epic’s Aura platform were cited as key steps in improving patient and provider experience. These efforts are also aimed at increasing operational efficiency and broadening the reach of Labcorp’s 6,500-plus diagnostic tests.
• Margin improvement via strategic actions: The Biopharma Laboratory Services segment benefited from previously announced restructuring in Early Development, leading to margin expansion. Management believes that completed strategic actions and top-line growth will continue to drive profitability improvements, particularly in the Biopharma segment.

Drivers of Future Performance

Labcorp’s outlook is driven by growth in specialty testing, digital consumer offerings, and margin expansion in both Diagnostics and Biopharma Laboratory Services.

• Specialty and consumer testing: Management believes ongoing demand for specialty diagnostics, combined with the rollout of new consumer genetic and biomarker tests, will drive higher volumes and support organic revenue growth. The company expects oncology and neurology to outpace broader market growth, benefiting from an aging population and rising health awareness.
• Operational efficiencies and Launchpad: Labcorp is relying on continued operating efficiency measures and its Launchpad initiative to deliver enterprise-wide margin expansion. Management anticipates further productivity gains as workflow improvements and technology adoption scale across both segments.
• Risks from regulatory and payer dynamics: The company acknowledged that headwinds could emerge from potential changes in ACA and Medicaid coverage, as well as ongoing reimbursement pressures from PAMA (Protecting Access to Medicare Act). However, management has factored these risks into its full-year guidance and plans to monitor developments closely, especially around payer mix and patient responsibility trends.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be monitoring (1) the scale and adoption of new specialty and consumer tests like ColoSense, (2) continued margin improvement from strategic actions in Early Development and efficiency initiatives under Launchpad, and (3) the progression of major health system partnerships and acquisitions. Developments around regulatory changes, especially PAMA and ACA, will also be closely watched for potential impact on Labcorp’s payer mix and revenue stability.

Labcorp currently trades at $312.29, up from $307.15 just before the earnings. Is there an opportunity in the stock? The answer lies in our full research report (it’s free).

Now Could Be The Perfect Time To Invest In These Stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.